Isomorphic Labs lands $2.1BN investment

Isomorphic Labs, the AI-focused drug discovery startup founded by Sir Demis Hassabis and spun out of Google DeepMind, has raised $2.1 billion in a Series B funding round. The round was led by Thrive Capital, with backing from existing investors Alphabet and its venture arm GV, alongside new participants including Singapore’s Temasek, Google’s CapitalG, and the UK Sovereign AI Fund. The funding follows Isomorphic Labs’ $600 million Series A in May 2023 and will scale its AI drug design engine, IsoDDE, which builds on DeepMind’s AlphaFold technology. The company aims to accelerate its pipeline of therapeutic programs, particularly for cancer and immune disorders, by expanding engineering, AI, and clinical talent. Hassabis, CEO of Isomorphic Labs and head of Google’s AI division, called the investment a ‘massive vote of confidence’ in its AI-first approach. He emphasized scaling the technology to ‘solve all disease,’ leveraging the new capital to refine and deploy IsoDDE globally. The funding will also support recruitment of top-tier experts in AI, drug design, and clinical research, positioning Isomorphic Labs as a leader in AI-driven pharmaceutical innovation. The company’s technology, rooted in DeepMind’s Nobel Prize-winning AlphaFold, predicts protein structures to streamline drug development.